Close Menu

NEW YORK – Thermo Fisher Scientific and Qiagen said today that they have amended the terms of their acquisition agreement, raising the offer price for Qiagen's stock to €43 ($49) per share to "reflect the fair value of the business."

Under the original agreement, announced March 3, Thermo Fisher was going to pay €39 per Qiagen share, a 23 percent premium over the closing price of Qiagen's common stock on March 2. The amendment raises the premium to 35 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.